Abstract: A kit having a means for isolating an immune cell population from a biological sample of a patient; and at least one agent capable of detecting NLGn4 gene product expression level.
Type:
Grant
Filed:
March 7, 2018
Date of Patent:
April 23, 2019
Assignee:
Hadasit Medical Research and Development Ltd.
Abstract: The present invention discloses a novel cervical collar for maintaining the airways in head and neck immobilized trauma patient open. This collar comprises a rigid motion-restricting frame (220, 230, 240, 270, 280) attached to the head (100); and, a jaw clasp (210, 290) attached to the jaw (110). The collar is simultaneously restricting the motion of the head (100) and neck while allowing motion of the jaw (110) to maintain open airways. A jaw clasp (290) useful for performing the jaw-thrust maneuver motion of the jaw (110) to maintain open airways is also presented. Said device comprising a plurality of movable fitting elements adapted to fit the jaw (110) tightly; and, a plurality of movable mover elements adapted to move the jaw (110).
Type:
Grant
Filed:
September 20, 2004
Date of Patent:
May 31, 2011
Assignees:
Hadasit Medical Research and Development Ltd., Ramot At Tel Aviv University Ltd.
Inventors:
Amit Gefen, Michal Peleg Lubovsky, Omri Lubovsky
Abstract: A composition for administration of a therapeutic compound to a multi-drug resistant cell in a person suffering from a drug-resistant cancer is described. The composition is composed of a carrier molecule and a folate targeting ligand, which is covalently attached to the carrier, and the therapeutic compound. In one preferred embodiment, the carrier is a liposome having a surface coating of hydrophilic polymer chains where a folate ligand is attached to the free distal end of at least a portion of the hydrophilic polymer chains, and the therapeutic agent is entrapped in the liposomes. The composition is effective to achieve accumulation of the therapeutic compound in the cell in an amount sufficient to be cytotoxic. Also described are methods for administering a therapeutic compound to a person suffering from a multi-drug resistant condition.
Type:
Application
Filed:
February 13, 2004
Publication date:
August 19, 2004
Applicants:
Alza Corporation, Hadasit Medical Research and Development Ltd.
Inventors:
Alberto A. Gabizon, Samuel Zalipsky, Dorit Goren-Rubel, Aviva T. Horowitz
Abstract: The present invention provides fibrin microbeads that are biologically active and comprise extensively cross-linked fibrin(ogen), and a method for preparing the fibrin microbeads. The present invention also provides a composition comprising cells bound to the fibrin microbeads, and methods for culturing and separating cells using the fibrin microbeads of the present invention. Finally, the present invention provides methods for transplanting cells and engineering tissue using the fibrin microbeads of the present invention.
Type:
Grant
Filed:
October 25, 2002
Date of Patent:
May 18, 2004
Assignee:
Hadasit Medical Research & Development Ltd.
Abstract: Fibrin microbeads are prepared containing extensively cross-linked fibrin (ogen) without using glutaraldehyde. The fibrin microbeads are preferably prepared by containing an aqueous solution containing fibrinogen, thrombin and Factor XIII with an oil heated to about 50-80° C. to form an emulsion and mixing the emulsion at 50-80° C. until fibrin microbeads containing extensively cross-linked fibrin (ogen) are obtained. The fibrin microbeads may have a diameter of about 50-200 microns and can contain a bioactive agent. The fibrin microbeads are used for binding cells such as when culturing or separating one cell type from another, or when transplanting cells or engineering tissue.
Type:
Grant
Filed:
September 15, 1998
Date of Patent:
January 7, 2003
Assignee:
Hadasit Medical Research & Development Ltd.
Abstract: Qualitative and quantitative methods of testing an agent for its potential at inhibiting glycosidase catalytic activity, the methods including the steps of interacting a glycosidase enzyme with a glycosidase substrate in a presence of the agent and qualitatively or quantitatively evaluating an effect of the agent on the catalytic activity of the glycosidase enzyme toward the glycosidase substrate. Preferably the glycosidase enzyme is a heparanase enzyme and the glycosidase substrate is, respectively, a heparanase substrate.
Type:
Grant
Filed:
July 10, 1998
Date of Patent:
February 20, 2001
Assignees:
Insight Strategy & Marketing Ltd., Hadasit Medical Research & Development Ltd.
Inventors:
Hanna Ben-Artzi, Maty Ayal-Hershkovitz, Israel Vlodavsky, Iris Pecker, Yoav Peleg, Daphna Miron